Global biopharmaceutical company Bristol Myers Squibb, based in Princeton, NJ, has earned the prestigious Global CEO Cancer Gold StandardTM accreditation for its ongoing commitment to reduce cancer risk for employees and their family members around the world.

“We are proud of this prestigious accreditation as it demonstrates our long-standing commitment to the health and safety of our employees,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol Myers Squibb. “As a company focused on helping patients with serious disease, we are committed to making health and wellness a priority for our employees and their families through a range of programs focused on mental and physical health.  We are proud to be recognized for these efforts, which we believe support our ability to deliver on our vision of transforming patients’ lives through science.”

This accreditation recognizes the Company’s exceptional efforts worldwide to reduce cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring broad access to innovative cancer therapies that are extending lives, improving quality of life and increasing productivity for employees and their family members around the globe.  

To be accredited as a Global Gold Standard organization, employers must achieve and maintain CEO Cancer Gold Standard accreditation in the U.S. and China, maintain a tobacco-free policy worldwide, and satisfy the essence and spirit of the five key areas of workplace wellness that are foundations of the Gold Standard.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit BMS.com.

Share This: